Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma
Status:
Terminated
Trial end date:
2018-11-01
Target enrollment:
Participant gender:
Summary
This Phase II clinical trial is an open label, single arm, multicenter study of the
combination of intravenously administered SGT-53 and oral temozolomide in patients with
confirmed glioblastoma who have proven tumor recurrence or progression. The objective of this
trial is to assess 6 month progression free survival (PFS), overall survival (OS), anti-tumor
activity, safety and possibly to evaluate, nanoparticle delivery to tumor site, and the
induction of apoptosis in the tumor..